Tebentafusp for uveal melanoma.

Published on Oct 8, 2021in Nature Reviews Clinical Oncology66.675
· DOI :10.1038/S41571-021-00572-3
David Killock9
Estimated H-index: 9
📖 Papers frequently viewed together
4 Authors (Kavita Mishra, ..., Devron H. Char)
BACKGROUND Uveal melanoma is a disease that is distinct from cutaneous melanoma, with a low tumor mutational burden and a 1-year overall survival of approximately 50% in patients with metastatic uveal melanoma. Data showing a proven overall survival benefit with a systemic treatment are lacking. Tebentafusp is a bispecific protein consisting of an affinity-enhanced T-cell receptor fused to an anti-CD3 effector that can redirect T cells to target glycoprotein 100-positive cells. METHODS In this o...
Cited By0
This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.